Home Featured Page 111

Featured

Latest

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Are You Attending PS2023? Here’s Where to Find Psychedelics Today in...

COMPASS Pathways’ key patents upheld by the US Patent and Trademark...

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the...

Cedar Clinical Research, by Numinus, the top enrolling clinical research site...

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in...

Psychedelics Weekly – Drug Testing and Harm Reduction, Ketamine vs. ECT,...

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan;...

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Numinus to Participate in a Water Tower Research Fireside Chat on...

atai Life Sciences to Participate in Upcoming June Investor Conferences

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Are You Attending PS2023? Here’s Where to Find Psychedelics Today in...

COMPASS Pathways’ key patents upheld by the US Patent and Trademark...

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the...

Cedar Clinical Research, by Numinus, the top enrolling clinical research site...

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in...

Psychedelics Weekly – Drug Testing and Harm Reduction, Ketamine vs. ECT,...

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan;...

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Numinus to Participate in a Water Tower Research Fireside Chat on...

atai Life Sciences to Participate in Upcoming June Investor Conferences

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY